Keystone Symposia in Vancouver

Cancer Vaccines

Fairmont Hotel Vancouver | Vancouver, British Columbia, Canada | January 20–24, 2019

Scientific Organizers:

Lélia Delamarre, Genentech, Inc., USA
Robert A. Seder, NIAID, National Institutes of Health, USA
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA

Organized in collaboration with Cancer Research UK

The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.

Plenary Session Topics:

- Identification of Mutated Neoantigens
- Workshop 1: Cancer Antigens
- Other Cancer Antigens
- Priming T Cells
- Workshop 2: Vaccine Platforms and Immune Monitoring
- Antigen-Presenting Cells
- Novel Cancer Vaccine Platforms I & II
- Tumor Microenvironment and Combination Therapies
- Workshop 3: Combination Therapies
- Immune Monitoring of T Cells

CANCER RESEARCH UK

Scholarship/Discounted Abstract Deadline: Oct 2, 2018; Abstract Deadline: Oct 24, 2018; Discounted Registration Deadline: Nov 27, 2018

Visit **www.keystonesymposia.org/19L2** for more details.






KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Cancer Vaccines (L2)

January 20-24, 2019 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada
Scientific Organizers: Lélia Delamarre, Robert A. Seder and Nina Bhardwaj
Organized in collaboration with Cancer Research UK

Sponsored by BioLegend, Inc. and Pfizer Inc.

Abstract & Scholarship Deadline: October 16, 2018 / Abstract Deadline: October 24, 2018 / Discounted Registration Deadline: November 27, 2018

SUNDAY, JANUARY 20

Arrival and Registration

MONDAY, JANUARY 21

Welcome and Keynote Session

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Cancer Vaccines: Overview

Ira Mellman, Genentech, Inc., USA
The Cancer Immune Cycle: Overview

Identification of Mutated Neoantigens

Timothy A. Chan, Memorial Sloan Kettering Cancer Center, USA
Neoantigen Identification

Karin U. Jooss, Gritstone Oncology, USA
Driving CD8+ T Cell Responses to Mutational Neoantigens in Tumors - Harnessing Immunogenic Viral Vectors

Lélia Delamarre, Genentech, Inc., USA
Neoantigen Identification

Short Talk(s) Chosen from Abstracts

Workshop 1: Cancer Antigens

Short Talks Chosen from Abstracts

Other Cancer Antigens

Stephen B. Baylin, Johns Hopkins University School of Medicine, USA
Immunogenicity of Transposable Elements in Cancer

Victor H. Engelhard, University of Virginia, USA
Post-Translationally Modified Cancer Neoantigens

Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
Targeting HPV Antigens by Vaccination

Short Talk(s) Chosen from Abstracts

Poster Session 1

TUESDAY, JANUARY 22

Priming T Cells

Rafi Ahmed, Emory University School of Medicine, USA
Talk Title to be Announced

E. John Wherry, University of Pennsylvania, USA
The Developmental Program of Exhausted T Cells

Pedro Romero, University of Lausanne, Switzerland
Programming T Cell Memory for Immunotherapy of Cancer

David B. Masopust, University of Minnesota, USA
Repurposing Antiviral T Cells to Fight Tumors

Short Talk(s) Chosen from Abstracts

Workshop 2: Vaccine Platforms and Immune Monitoring

Short Talks Chosen from Abstracts

Antigen Presenting Cells

Karin Loré, Karolinska Institutet, Sweden
Understanding Innate Immune Mechanisms Dictating Vaccine Responses

Sebastian Amigorena, Institut Curie, France
Dendritic Cell Biology

Marc Y. Dalod, CNRS, France
Deciphering the Role of cDC1 in Anti-Tumor Immunity

Short Talk(s) Chosen from Abstracts

Poster Session 2

WEDNESDAY, JANUARY 23

Novel Cancer Vaccine Platforms I

David B. Weiner, Wistar Institute, USA
DNA-Based Vaccines

John C. Bell, Ottawa Hospital Research Institute, Canada
Virus-Based Vaccines

Ugur Sahin, BioNTech AG, Germany
RNA-Based Vaccines

Robert A. Seder, NIAID, National Institutes of Health, USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Novel Cancer Vaccine Platforms II

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Building Better Personal Cancer Vaccines

Nina Bhardwaj, Icahn School of Medicine at Mt Sinai, USA
DC-Targeting Vaccines

Short Talk(s) Chosen from Abstracts

Poster Session 3

THURSDAY, JANUARY 24

Tumor Microenvironment and Combination Therapies

Joshua D. Brody, Icahn School of Medicine at Mount Sinai, USA
In situ Vaccination for Cancer

Shannon J. Turley, Genentech, Inc., USA
TGFbeta in Cancer

Thomas Gajewski, University of Chicago, USA
Regulation of Anti-Tumor Immunity

Miriam Merad, Mount Sinai School of Medicine, USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Workshop 3: Combination Therapies

Short Talks Chosen from Abstracts

Immune Monitoring of T Cells

Garry P. Nolan, Stanford University, USA
Talk Title to be Announced

Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
NKG2A Blockade Potentiates CD8+ T-Cell Immunity Induced by Therapeutic Cancer Vaccines

Evan W. Newell, Fred Hutchinson Cancer Research Center, USA
Asking T Cells About What They See in Cancer

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Vaccines (L2)

January 20-24, 2019 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Scientific Organizers: Lélia Delamarre, Robert A. Seder and Nina Bhardwaj

Organized in collaboration with Cancer Research UK

Sponsored by BioLegend, Inc. and Pfizer Inc.

Abstract & Scholarship Deadline: October 16, 2018 / Abstract Deadline: October 24, 2018 / Discounted Registration Deadline: November 27, 2018

FRIDAY, JANUARY 25

Departure